Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes; Congenital Bone Marrow Failure Syndromes; Inherited Metabolic Disorders (IMD); Hereditary Anemias; Patients With Sickle Disease Presenting Specific SymptomsInterventions: Drug: Hydroxyurea; Drug: Alemtuzumab; Drug: Fludarabine; Drug: Melphalan; Drug: ThiotepaSponsor: University of PittsburghRecruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials